N/A N=40 The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome
Metabolic Syndrome · Type 2 Diabetes · Cardiovascular Disease
Primary: Insulin Resistance — 6.06; 5.72 HOMA-IR index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=213 A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 — -0.77; -0.44 Percent — p=0.035
N/A N=32 Prediction of Development of Scapular Notching Following Reverse Total Shoulder Arthroplasty
Osteoarthritis · Rotator Cuff Tear Arthropathy · Reverse Total Shoulder Arthroplasty
Primary: Actual Versus Predicted Scapular Notching — 96.6 percentage of accurate predictions
Phase 3 N=740 Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)
Chronic Low Back Pain
Primary: Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind…
Phase 2 N=70 Transcranial Magnetic Stimulation for Tinnitus
Tinnitus
Primary: Change in Tinnitus Functional Index (TFI) Score — -13.8; -2.9 units on TFI scale; change from baseline
Phase 3 N=160 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — NA; 8.38 months — p=<0.0001
N/A N=100 Amsterdam Stool Scale: Usefulness in Clinical Setting
Stool Assessment
Primary: Interrater Variability (IV) — 0.79; 0.87; 0.81; 0.44 kappa value
Phase 1 N=88 Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 3; 10; 8 Participants
N/A N=86 Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Early Allograft Dysfunction · Ischemic Reperfusion Injury · Liver Transplantation
Primary: Early Allograft Dysfunction — 6; 18 Participants
Phase 3 N=598 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -2.05; -1.19; -1.35 % of hemoglobin — p=<0.0001
Phase 1 N=40 Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants
Healthy Volunteers
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 50.0; 50.0; 33.3; 66.7 percentage of participants
N/A N=34 A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans
Asthma
Primary: Change in Asthma Control Test Scores — 21; 22; 20; 21 units on a scale
N/A N=28 Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)
Venous Leg Ulcer · Chronic Venous Insufficiency · Venous Stasis Ulcer
Primary: Number of Participants Who Agreed With Tolerance and Comfort Questionnaire Items After Using a Dual Action Pneumatic Compression Device — 12; 8; 9; 15 Participants
Phase 2 N=32 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: 5-Year Relapse-free Survival Rate — 53 percentage of participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57